SciVision Biotech Inc
TWSE:1786

Watchlist Manager
SciVision Biotech Inc Logo
SciVision Biotech Inc
TWSE:1786
Watchlist
Price: 90.7 TWD -1.41% Market Closed
Market Cap: 6.4B TWD
Have any thoughts about
SciVision Biotech Inc?
Write Note

SciVision Biotech Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SciVision Biotech Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
SciVision Biotech Inc
TWSE:1786
Additional Paid In Capital
NT$841.6m
CAGR 3-Years
10%
CAGR 5-Years
6%
CAGR 10-Years
5%
M
Medtecs International Corporation Ltd
SGX:546
Additional Paid In Capital
$4.7m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
0%
V
Visco Vision Inc
TWSE:6782
Additional Paid In Capital
NT$1.4B
CAGR 3-Years
235%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
Pegavision Corp
TWSE:6491
Additional Paid In Capital
NT$4.3B
CAGR 3-Years
33%
CAGR 5-Years
78%
CAGR 10-Years
N/A
OK Biotech Co Ltd
TWSE:4155
Additional Paid In Capital
NT$890.5m
CAGR 3-Years
16%
CAGR 5-Years
26%
CAGR 10-Years
N/A
No Stocks Found

SciVision Biotech Inc
Glance View

Market Cap
6.4B TWD
Industry
Health Care

SciVision Biotech, Inc. engages in the research, development, and production of hyaluronic acid medical products. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2010-12-29. The firm primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The firm is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The firm operates its business in the Americas, Europe, Asia, Middle East and Africa.

Intrinsic Value
178.54 TWD
Undervaluation 49%
Intrinsic Value
Price

See Also

What is SciVision Biotech Inc's Additional Paid In Capital?
Additional Paid In Capital
841.6m TWD

Based on the financial report for Sep 30, 2024, SciVision Biotech Inc's Additional Paid In Capital amounts to 841.6m TWD.

What is SciVision Biotech Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
5%

Over the last year, the Additional Paid In Capital growth was 20%. The average annual Additional Paid In Capital growth rates for SciVision Biotech Inc have been 10% over the past three years , 6% over the past five years , and 5% over the past ten years .

Back to Top